---
title: "PDS Biotechnology 2026 年第一季度財報預覽"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/286130832.md"
description: "PDS Biotechnology (PDSB) 將於 5 月 13 日市場開盤前公佈其第一季度財報。市場普遍預期每股收益（EPS）為-0.14 美元，同比增長 33.3%，預計收入為 0 萬美元。在過去三個月中，EPS 預期有一次上調，沒有下調"
datetime: "2026-05-12T16:11:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286130832.md)
  - [en](https://longbridge.com/en/news/286130832.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286130832.md)
---

# PDS Biotechnology 2026 年第一季度財報預覽

PDS Biotechnology (PDSB) is scheduled to announce Q1 earnings results on Wednesday, May 13th, before market open. The consensus EPS Estimate is -$0.14 (+33.3% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. More on PDS Biotechnology PDS Biotechnology Corporation (P...

### 相關股票

- [PDSB.US](https://longbridge.com/zh-HK/quote/PDSB.US.md)

## 相關資訊與研究

- [PDS Biotechnology 更新了公司演示，重點介紹了第三階段的 VERSATILE-003，39.3 個月的中位總生存期以及即將到來的催化劑](https://longbridge.com/zh-HK/news/284050202.md)
- [PDS Biotechnology（納斯達克代碼：PDSB）被 HC Wainwright 給予買入評級](https://longbridge.com/zh-HK/news/282880979.md)
- [Siebert Financial 的 GAAP 每股收益為-$0.05，營收為$23.5 百萬美元](https://longbridge.com/zh-HK/news/286621223.md)
- [台光電第 1 季 EPS 14.9 元 法人看好全年上看 76.2 元](https://longbridge.com/zh-HK/news/285833087.md)
- [Eagle Point Income Company 的 GAAP 每股收益為 0.36 美元，超出預期 0.03 美元](https://longbridge.com/zh-HK/news/286909996.md)